Health Stocks in Motion
Updated from 2:19 p.m. EST
Shares of NitroMed (NTMD) were among the worst-performing health-related stocks Friday, falling 12.8% after the company posted a fourth-quarter loss that just missed expectations.
The company posted a loss of $9.7 million, or 36 cents a share, on sales of $9.5 million. Analysts polled by Thomson First Call were expecting a loss of 35 cents a share. A year ago, the company posted a loss of $10.5 million, or 71 cents a share, on sales of $7.2 million. Shares traded down $2.73 to $18.62.
Horizon Health (HORC) rose 9.7% after the company said it priced 1.5 million shares at $36.25 each in a follow-on stock offering. The stock closed Thursday at $36.40. Horizon said that it would use the $50.6 million in net proceeds to pay down $34.5 million in debt and use the rest for general corporate purposes, including acquisitions. J.P. Morgan led the underwriting syndicate. Shares traded up $3.52 to $39.92.Shares of Nanogen (NGEN) rose 4.1% after the company said it received a patent related to ligation-based strand displacement amplification technology, which will make the detection of infectious diseases much quicker. The intellectual property pertains to research that was conducted in collaboration with Becton Dickinson (BDX). Shares traded up 16 cents to $4.10. Savient Pharmaceuticals (SVNT) traded actively after the company halted a phase II clinical trial for its Prosaptide compound. The trial was designed to test the safety and efficacy of the drug in HIV and AIDS patients who suffered from peripheral neuropathic pain. The trial was halted at the recommendation of the Data and Safety Monitoring Board, which discussed the results of the analysis of the unblended study at a meeting in late February. On March 10, the safety monitoring board wrote a letter to Savient, saying that even if the trial were to continue, there was little chance of achieving statistical significance at the analgesia efficacy endpoint. Shares traded up 10 cents to $2.64 on volume of more than 1.15 million shares.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV